'U.S. FDA Declines To Approve Regeneron High-dose Eylea'
Portfolio Pulse from Happy Mohamed
The U.S. Food and Drug Administration (FDA) has declined to approve a higher-dose version of Regeneron Pharmaceuticals' Eylea treatment. This decision could impact Regeneron's ability to compete against fast-gaining rivals in the eye drug market.
June 27, 2023 | 6:55 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Regeneron Pharmaceuticals' plans to defend its Eylea drug against rivals may be impacted as the FDA declined to approve a higher-dose version of the treatment.
The FDA's decision not to approve a higher-dose version of Eylea could potentially hinder Regeneron's ability to compete against fast-gaining rivals in the eye drug market. This could negatively impact the company's market share and revenues in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100